Business
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December ...
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Total net revenue of $15.2 million","length":34,"tagName":"p"},{"type":"text","content":"Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments","length":75,"tagName":"p"},{"type":"text","content":"$30.0 million cash balance at December 31, 2025","length":47,"tagName":"p"},{"type":"text","content":"Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market","length":263,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time","length":94,"tagName":"p"},{"type":"text","content":"DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 second quarter.","length":373,"tagName":"p"},{"type":"text","content":"The Company is also providing an update on its recent commercial launch of EXXUA, a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration ("FDA") for the treatment of MDD in adults.","length":260,"tagName":"p"},{"type":"text","content":"Q2 Fiscal 2026 Highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenue of $15.2 million versus $16.2 million in Q2 fiscal 2025.","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"ADHD Portfolio, which consists of attention deficit hyperactivity disorder ("ADHD") products, net revenue was $13.2 million versus $13.8 million in Q2 fiscal 2025.","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Pediatric Portfolio, which consists of a line of legacy products, net revenue was $1.7 million versus $2.4 million in Q2 fiscal 2025.","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"EXXUA was made commercially available in mid-December 2025, and therefore minimal initial stocking net revenue of $0.2 million occurred during the quarte...